-On Friday 19 June- over 260 people joined our webinar, in partnership with Lymphoma Action, to hear our panel of UK experts answer some of the most commonly asked questions around COVID-19 and Waldenstrom’s macroglobulinaemia (WM).… Continue reading →
In the first head-to-head comparison of Bruton tyrosine kinase (BTK) inhibitors, zanubrutinib demonstrated statistically significant and clinically meaningful advantages in safety and tolerability in patients with Waldenström macroglobulinemia (WM) compared with ibrutinib. Although zanubrutinib yielded a numerically higher response rate… Continue reading →
In this video, an international panel of experts sat down with Oncology Learning Network to discuss the 3 Bruton’s tyrosine kinase (BTK) inhibitors active in the treatment of Waldenström macroglobulinemia (WM): ibrutinib, acalabrutinib, and zanubrutinib.
The new reality with Covid-19 has changed how we are all living. In these unprecedented times, Canadian WM patients have continued to support each other, but are doing it differently. Face to face meetings have allowed us to mingle and… Continue reading →
Fifty WMers from the Philly WM Support Group enjoyed a lively, engaging and informative conversation with Dr. Jorge Castillo, Clinical Director of the Bing Center for Waldenström’s Macroglobulinemia at Dana-Farber Cancer Institute. They had a… Continue reading →
Dr. Jorge Castillo – Associate Professor of Medicine, Harvard University – presenting “Treatment around the corner for Waldenstroms Macroglobulinemia” at the 2019 WMFC Educational Forum Toronto – April 2019